Wz3146

PC9-1 cells were plated in duplicate in six-well plates with erlotinib-free media at 40,000 cells per well (Supplementary Fig. 2b). Media was changed to drug-containing media (described below) after allowing cells to adhere overnight. Plates were treated with various drugs either singly in erlotinib-free media or in combination with erlotinib media. The following drugs were used: 0.1 μM WZ8040 (Selleckchem, Cat.#S1179), 0.1 μM WZ3146 (Selleckchem, Cat.#S1170), 0.1 μM SGX-523 (Selleckchem, Cat.#S1112), 0.0316 μM Crizotinib (PF-02341066; Selleckchem, Cat.#S1068) and 0.02 μM trichostatin A (Selleckchem, Cat.#S1045). One pair of wells was used as controls with no drug in either erlotinib-free media or erlotinib media. The cells were grown for 14 days, with media being changed every 3 days. Cells were imaged every 3 days at × 10 magnification with phase-contrast on a Nikon Ti Eclipse.

The human neuroblastoma cell line SH-SY5Y was cultured in RMPI 1640 medium containing 15% fetal bovine serum (FBS). Cells were seeded into 96-well plates (10 000 per well), treated for 24 h with different concentration of purvalanol A, idarubicin, WZ3146, AZD-8055, TG-101348 (10^-8~10^-5 mol/L, all purchased from Selleck, Shanghai, China). The cells were incubated at 37 °C for 2 h with CCK-8 Kit (Dojindo, Tokyo, Japan). Medium without cells was incubated with CCK8 as blank well. The optical densities (ODs) were checked at 450 nm using a microplate reader. The inhibition rate was calculated as following: (ODdrug-ODblank)/(ODcontrol-ODblank) × 100%.